Reviva Pharmaceuticals (RVPH) Competitors $0.87 -0.01 (-0.65%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.89 +0.03 (+2.90%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. PRQR, TNGX, FDMT, TLSA, LFVN, LRMR, NBTX, PBYI, CYBN, and ACRSShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include ProQR Therapeutics (PRQR), Tango Therapeutics (TNGX), 4D Molecular Therapeutics (FDMT), Tiziana Life Sciences (TLSA), LifeVantage (LFVN), Larimar Therapeutics (LRMR), Nanobiotix (NBTX), Puma Biotechnology (PBYI), Cybin (CYBN), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. ProQR Therapeutics Tango Therapeutics 4D Molecular Therapeutics Tiziana Life Sciences LifeVantage Larimar Therapeutics Nanobiotix Puma Biotechnology Cybin Aclaris Therapeutics Reviva Pharmaceuticals (NASDAQ:RVPH) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Which has more volatility and risk, RVPH or PRQR? Reviva Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Which has better earnings & valuation, RVPH or PRQR? ProQR Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$39.26M-$0.91-0.95ProQR Therapeutics$18.91M11.08-$30.43M-$0.34-5.85 Does the media favor RVPH or PRQR? In the previous week, ProQR Therapeutics had 15 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 18 mentions for ProQR Therapeutics and 3 mentions for Reviva Pharmaceuticals. ProQR Therapeutics' average media sentiment score of 0.68 beat Reviva Pharmaceuticals' score of -0.33 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RVPH or PRQR? Reviva Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 1,053.54%. ProQR Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 339.70%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community prefer RVPH or PRQR? ProQR Therapeutics received 309 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 90.63% of users gave Reviva Pharmaceuticals an outperform vote while only 62.13% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformReviva PharmaceuticalsOutperform Votes2990.63% Underperform Votes39.38%ProQR TherapeuticsOutperform Votes33862.13% Underperform Votes20637.87% Do institutionals and insiders hold more shares of RVPH or PRQR? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is RVPH or PRQR more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Reviva Pharmaceuticals' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -252.53% ProQR Therapeutics -134.31%-71.58%-19.70% SummaryReviva Pharmaceuticals and ProQR Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.52M$6.86B$5.57B$8.05BDividend YieldN/A2.89%5.36%4.23%P/E Ratio-0.787.5422.8119.02Price / SalesN/A259.70406.32107.04Price / CashN/A65.8538.1834.62Price / Book4.336.566.794.34Net Income-$39.26M$143.88M$3.23B$248.27M7 Day Performance-0.40%2.90%2.18%2.51%1 Month Performance63.57%15.99%11.52%13.39%1 Year Performance-72.91%-3.19%16.78%5.08% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.5814 of 5 stars$0.87-0.7%$10.00+1,053.5%-72.9%$40.52MN/A-0.785Short Interest ↑News CoveragePRQRProQR Therapeutics2.9304 of 5 stars$1.54+7.7%$9.50+516.9%-1.0%$162.03M$18.91M-4.81180Upcoming EarningsTNGXTango Therapeutics2.3442 of 5 stars$1.49+2.1%$12.33+727.7%-80.2%$161.08M$42.07M-1.2690Upcoming EarningsPositive NewsFDMT4D Molecular Therapeutics2.6126 of 5 stars$3.34flat$26.71+699.8%-85.7%$154.65M$37,000.00-1.17120Upcoming EarningsTLSATiziana Life Sciences0.3167 of 5 stars$1.31-3.7%N/A+71.8%$153.07MN/A0.008Gap DownLFVNLifeVantage4.1829 of 5 stars$12.14-1.0%$30.50+151.2%+81.3%$152.37M$212.15M21.68260Upcoming EarningsPositive NewsHigh Trading VolumeLRMRLarimar Therapeutics1.6622 of 5 stars$2.35+0.9%$19.63+735.1%-61.8%$150.47MN/A-2.0430Earnings ReportUpcoming EarningsAnalyst RevisionNews CoverageNBTXNanobiotix1.2704 of 5 stars$3.19+1.3%$8.00+150.8%-43.5%$150.35M$-11,609,000.000.00100Positive NewsPBYIPuma Biotechnology3.7695 of 5 stars$2.98-0.7%$7.00+134.9%-34.0%$147.84M$230.47M6.21200Upcoming EarningsAnalyst DowngradeAnalyst RevisionNews CoverageCYBNCybin2.4025 of 5 stars$6.87-1.7%$86.00+1,151.8%N/A$147.55MN/A-1.5750News CoverageACRSAclaris Therapeutics3.1665 of 5 stars$1.36+1.5%$11.67+757.8%+5.9%$147.26M$18.72M-2.62100Upcoming EarningsPositive News Related Companies and Tools Related Companies PRQR Alternatives TNGX Alternatives FDMT Alternatives TLSA Alternatives LFVN Alternatives LRMR Alternatives NBTX Alternatives PBYI Alternatives CYBN Alternatives ACRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RVPH Stock Free RVPH Stock Alerts